LUCIA, the second of 2 pivotal phase 3 trials in neovascular (wet) age-related macular degeneration (AMD), missed its primary ...

The 2 complement inhibitors approved by the US Food and Drug Administration (FDA) for geographic atrophy (GA) secondary to ...

At AAO 2026, Anjum F. Koreishi, MD, shared how to prevent complications after cataract surgery in patients with uveitis.

At AAO 2026, Adam, MD, shares Yamane technique pearls, from docking the trailing haptic to preventing tilt and haptic ...

David F. Chang, MD, shares how to set realistic refractive IOL expectations and streamline patient counseling.

Taken together, these three responses point to gaps beyond the next therapy: in how academic medicine is valued, in what ...

Timothy Janetos, MD, explained when to refer uveitis to a specialist and why access to uveitis care remains limited.

The FDA has approved Enspryng (satralizumab, Genentech) for thyroid eye disease (TED), making the drug the first subcutaneous ...

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...

In addition to the results, Roche also announced that the US Food and Drug Administration (FDA) has accepted the company’s ...

David F. Chang, MD, explained how offering complementary refractive IOLs reduces patient anxiety and indecision.

Ryzumvi (phentolamine ophthalmic solution 0.75%) is approved for the treatment of presbyopia in adults. It is also approved for pharmacologically induced mydriasis produced by adrenergic agonists or ...